Belite Bio Inc ADR (BLTE NASDAQ) stock market data APIs
$154.3465
-11.27(-7.3%)
as of November 6, 2026
Try our APIs with
free plan!
Belite Bio Inc ADR Financial Data Overview
Price chart is built with
Anychart
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Prev. Close
154.3465
Open
143.0757
High
154.8235
Low
140.3687
52 wk Range
102-200
Market Cap
6 210 M
Shares Outstanding
40 272 K
Beta
-1.193
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Belite Bio Inc ADR (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Belite Bio Inc ADR data using free add-ons & libraries
Get Belite Bio Inc ADR Fundamental Data
Belite Bio Inc ADR Fundamental data includes:
- Net Revenue:
- EBITDA: -118 494 000
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-11-12
- EPS/Forecast: -0.73
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Belite Bio Inc ADR News
New
Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results
Belite Bio, Inc SAN DIEGO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) ("Belite Bio®" or the "Company"), a clinical-stage drug development company focused on advancing novel the...
Belite Bio Announces Uplisting to the Nasdaq Global Select Market
Belite Bio, Inc SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) ("Belite Bio®" or the "Company"), a clinical-stage drug development company focused on advancing novel the...
Belite Bio Stock In Focus After Stargardt Drug Filings In Three Markets
Belite Bio submitted Marketing Authorization Applications for tinlarebant to regulators in Singapore, the United Kingdom, and Switzerland under the Access Consortium framework for treating Stargardt d...
Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1
Belite Bio, Inc If approved, tinlarebant would be the first-ever approved treatment for Stargardt Disease Type 1 in Singapore, United Kingdom, and Switzerland Access pathway submission combined with ...
Get Belite Bio Inc ADR fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.